anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LUMAKRAS can cause hepatotoxicity and increased ALT or AST which may lead to drug-induced liver injury and hepatitis.

In the pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg [see Adverse Reactions (6.1)], hepatotoxicity occurred in 27% of patients, of which 16% were Grade ≥ 3. Among patients with hepatotoxicity who required dosage modifications, 64% required treatment with corticosteroids.

In this pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg, 17% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); of which 9% were Grade ≥ 3. The median time to first onset of increased ALT/AST was 6.3 weeks (range: 0.4 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 9% of patients treated with LUMAKRAS. LUMAKRAS was permanently discontinued due to increased ALT/AST in 2.7% of patients. Drug-induced liver injury occurred in 1.6% (all grades) including 1.3% (Grade ≥ 3).

In this pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg, a total of 40% patients with recent (≤ 3 months) immunotherapy prior to starting LUMAKRAS had an event of hepatotoxicity. An event of hepatotoxicity was observed in 18% of patients who started LUMAKRAS more than 3 months after last dose of immunotherapy and in 17% of those who never received immunotherapy. Regardless of time from prior immunotherapy, 94% of hepatotoxicity events improved or resolved with dosage modification of LUMAKRAS, with or without corticosteroid treatment.

Monitor liver function tests (ALT, AST, alkaline phosphatase and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, reduce the dose or permanently discontinue LUMAKRAS based on severity of the adverse reaction [see Dosage and Administration (2.3) and Adverse Reactions (6.1)]. Consider administering systemic corticosteroids for the management of hepatotoxicity.
PURPOSE: This is a retrospective study of one-stage anterior sagittal sphincter saving anorectoplasty (ASSSARP) for repairing rectovestibular fistula (RVF) including operative details and postoperative complications, functional and cosmetic outcome.
PATIENTS AND METHODS: Records of 41 cases of RVF, managed between April 2010 and September 2019 by one-stage ASSSARP, were reviewed. Preoperative preparation, both early and late postoperative care & complications, hospital stay, and functional & cosmetic outcomes were reported.
RESULTS: The mean age was 6.6 months. Vaginal tear occurred in 5/41 cases, and distal rectal tears in 4/41 cases. Thirteen patients suffered mild superficial wound inflammation; while Skin dehiscence; occurred in five patients. No colostomy or redo was needed. The mean hospital stay was 6.1 days. Mean follow-up was 43.13 months; (Range; 24-100 months). Subclinical anal stricture was detected in six patients. Constipation occurred in 14 cases. Soiling grade I occurred in five patients. Thirty-two patients reached past the age of three years; two of whom showed cough/diarrhea incontinence.
CONCLUSION: One-stage ASSSARP is safe and gives functional and cosmetic results comparable to other techniques. It provides better access during RVF repair. The avoidance of muscle incision protects against muscle breakdown, if infection sets in, and thus against incontinence. It avoids the morbidity, cost and psychological burden of performing a three-stage repair.
BACKGROUND AND AIM: Several agents are under investigation for nonalcoholic fatty liver disease (NAFLD). We assessed the comparative efficacy of pharmacologic interventions for patients with NAFLD focusing on magnetic resonance imaging (MRI) biomarkers.
METHODS: We searched Medline, Embase, and CENTRAL. We included randomized controlled trials of more than 12 weeks of intervention that recruited patients with biopsy-confirmed or MRI-confirmed NAFLD and assessed the efficacy of interventions on liver fat content (LFC) and fibrosis by means of MRI. We performed random-effects frequentist network meta-analyses and assessed confidence in our estimates using the CINeMA (Confidence in Network Meta-Analysis) approach.
RESULTS: We included 47 trials (8583 patients). Versus placebo, thiazolidinediones were the most efficacious for the absolute change in LFC, followed by vitamin E, fibroblast growth factor (FGF) analogs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with mean differences ranging from -7.46% (95% confidence interval [-11.0, -3.9]) to -4.36% (-7.2, -1.5). No differences between drug classes were evident. Patients receiving GLP-1 RAs or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs were more likely to achieve ≥30% relative reduction in LFC. Among agents, efruxifermin produced the largest reduction in LFC compared to placebo [-13.5% (-18.5, -8.5)], followed by pioglitazone, while being superior to most interventions. The effect of interventions on magnetic resonance elastography assessed fibrosis was small and insignificant. The confidence in our estimates was low to very low.
CONCLUSIONS: Several drug classes may reduce LFC in patients with NAFLD without a significant effect on fibrosis; nevertheless, trial duration was small, and confidence in the effect estimates was low.
PURPOSE: To provide the subject new compound produced by culturing a valinoctin-producing microorganism belonging to the genus Streptomyces, effective for inhibiting farnesyl protein transferase and suppressing the proliferation of human cancer cell, having low toxicity and useful e.g. for a carcinostatic agent. CONSTITUTION: This new compound is valinoctin A or valinoctin B expressed by formula I (R is H for valinoctin A and methyl for valinoctin B), its acid addition salt or a compound of formula II (R<1> is an alkyl) consisting of an alkyl ester of the compound of formula I. The compound is effective for inhibiting farnesyl protein transferase and suppressing the proliferation of human cancer cell. The valinoctin A and/or valinoctin B can be separated from the cultured product of a microorganism belonging to the genus Streptomyces and capable of producing valinoctin A and valinoctin B [e.g. Streptomyces sp. MJ858-NF3 (FERM P-14082)].
Older Veterans with serious mental illness (schizophrenia, schizoaffective disorder, bipolar disorder) have significantly compromised physical function that leads to heightened rates of falls, hospitalizations, nursing home admissions, as well as early mortality. In fact, this population's physical function is compromised across multiple domains including mobility, endurance, and strength. Exercise is effective for increasing all domains of physical function (i.e., mobility, endurance, strength) in older Veterans. But, environmental difficulties (e.g., lack of transportation), low motivation, and medical issues affecting older Veterans with serious mental illness contribute to low engagement rates and high dropout rates in facility-based exercise programs. Individualized home-based exercise programs, which are safe and effective for older Veterans with health challenges, could address the main barriers to exercise in older Veterans with serious mental illness by promoting greater accessibility and individual tailoring. The purpose of this study is to evaluate the feasibility and acceptability of a 12-week home-based exercise program for older Veterans with serious mental illness.
Zolpidem Tartrate Sublingual Tablet is to be taken in bed when a patient wakes in the middle of the night and has difficulty returning to sleep. Zolpidem Tartrate Sublingual Tablet should only be taken if the patient has at least 4 hours of bedtime remaining before the planned time of waking [see Warnings and Precautions (5.1)]. 

Zolpidem Tartrate Sublingual Tablet should be placed under the tongue and allowed to disintegrate completely before swallowing. The tablet should not be swallowed whole. For optimal effect, Zolpidem Tartrate Sublingual Tablet should not be administered with or immediately after a meal. The blister should be removed from the pouch just prior to dosing.
A cationic polyester, a preparation method therefor and the use thereof. The cationic polyester is a hyperbranched polymer, which is formed by polymerizing three monomers, monomer P, monomer S and monomer M, or two monomers, the monomer P and monomer S, with monomer T, an end group of said hyperbranched polymer being modified with group E. The monomer P is a lactone. The monomer S is an organic acid of which an end group contains two or more carboxyl groups. The monomer M is a compound containing two hydroxyl groups and one secondary amino group or tertiary amino group. The monomer T is a compound containing three or more hydroxyl groups. An end group modifying compound E which provides the group E modification is a compound containing at least one primary amino group, secondary amino group or tertiary amino group. When being used for nucleic acid drug delivery, the cationic polyester can remarkably improve the nucleic acid transfection efficiency and has lower cytotoxicity, and thus can be used clinically. In addition, the cationic polyester has low preparation cost and is environment-friendly and pollution-free.
An oil-in-water emulsion for application on a skin surface is disclosed. The emulsion comprises an oily phase and an aqueous phase. The oily phase comprises a first lipid of vegetable or animal origin. The emulsion is stabilized by containing at least one surfactant/emulsifier. The surfactant/emulsifier is substantially removed from a skin surface onto which the emulsion has been applied and from the emulsion by flushing with a liquid, thereby leaving at least a part of the oily phase on the skin. When the emulsion is diluted with tap water, which has a degree of hardness of about 18 degrees in a volume of 100 parts of water to one part of the emulsion at ambient temperature, it is separated into at least two distinct phases after standing for 24 hours at ambient temperature. The emulsion has a pH value of at least about 6 and at least about 50% w/w of the total concentration of the surfactant/emulsifier which is a fatty acid derivative. The fatty acid derivative has a fatty acid component which is a saturated or unsaturated C 10 -C 24  hydrocarbon carboxylic acid or mixtures thereof. The emulsion can be used in a method for cleansing or conditioning a skin surface, for treating human skin, for treating mammals against parasites belonging to the phylum Arthropoda and for protecting human skin against the sun.
Techniques are provided for mobile platform based detection and prevention (or mitigation) of hearing loss. An example system may include a hearing loss indicator data generation circuit configured to measure hearing loss indicator data associated with use of the device by a user. The hearing loss indicator data may include ambient sound characteristics, user speech volume level and user volume setting of the device. The system may also include an audio context generation circuit configured to estimate context data associated with use of the device. The context data may be based on classification of audio input to the device and on the location of the device. The system may further include an interface circuit configured to collect the hearing loss indicator data and the context data over a selected time period and provide the collected data to a hearing loss analysis system at periodic intervals.
The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of SCENESSE. Warn patients of the risk of hypersensitivity reactions, including anaphylaxis. If a serious hypersensitivity reaction occurs, initiate appropriate therapy and remove the SCENESSE implant if needed [ see Dosage and Administration]. The patient should not receive any further treatment with SCENESSE. [ see Contraindications]. 

SCENESSE may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect. A full body skin examination (twice yearly) is recommended to monitor pre-existing and new skin pigmentary lesions.
ABSTRACT OF THE DISCLOSURE         Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed.    Such compositions soften skin, strengthen nails and provide other benefits when applied topically.  And, MSM compositions may also be administered orally, by injection and by inhalation.         In many instances, the effectiveness of MSM compo-sitions is enhanced when such compositions contain carbamide (urea).  Also, carbamide compositions are stabilized when they contain the MSM.        For topical administration, MSM compositions may be formulated in creams, lotions or gels which may be used alone or to serve as stable, neutral vehicles for other skin condi-tioning substances or therapeutically active drugs.  Aqueous MSM solutions are suitable blood diluents.
Compsns. comprise (a) a mixt. of at least 2 vegetable oils including jojoba oil and sunflower oil, and (b) at least one pre- extracted unsaponifiable fraction. Component (b) is pref. an unsaponifiable fraction or concentrate derived from soya, avocado, corn or sunflower oils or their mixts. The compsns. can be used in a wide range of cosmetic products, including skin and hand creams and lotions, bath oils, etc. They have a high penetrating power and a non-greasy feel.
Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
BACKGROUND: Surgical chest masculinization procedures, especially gender-affirming top surgery (GATS), are becoming increasingly prevalent in the USA. While a variety of surgical techniques have been established as both safe and effective, there is limited research examining ideal aesthetic nipple appearance and incision scar pattern. This study employs patient images to understand the public's perception on top surgery outcomes when adjusting for BMI ranges and Fitzpatrick skin types.
METHODS: Images from RealSelf modified via Adobe Photoshop depicted various scar types and nipple-areolar complex (NAC) sizes/positions. A Qualtrics survey was distributed utilizing Amazon Mechanical Turk. Statistical analysis was performed through JMP Pro 17 for ordinal and categorical values, with a p value less than or equal to 0.05 statistically significant.
RESULTS: A moderately sized and laterally placed NAC was preferred. A transverse scar that resembles the pectoral border between the level of the inframammary fold and pectoral insertion was deemed most masculine and aesthetic. Majority of results demonstrated that this is unaffected by Fitzpatrick skin types. Increased BMI images impacted public preferences, as a nipple placed farther from the transverse incision (p = 0.04) and a transverse scar position closer to the IMF was preferred in higher BMI patients.
CONCLUSIONS: An understanding of the most popular NAC and scar choices, as well as how these factors may differ when considering a Fitzpatrick skin type or BMI categorization was attained. This validates the importance of patient-centered approach when employing surgical techniques in GATS. Future studies intend to obtain reports from actual patients considering GATS.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable.
Methylphenidate is a mild central nervous system stimulant.

The mode of action in man is not completely understood, but methylphenidate presumably activates the brain stem arousal system and cortex to produce its stimulant effect.

There is neither specific evidence which clearly establishes the mechanism whereby methylphenidate produces its mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.

Methylphenidate hydrochloride in the extended-release tablets is more slowly but as extensively absorbed as in the regular tablets. Relative bioavailability of the extended-release tablet compared to the methylphenidate hydrochloride tablet, measured by the urinary excretion of methylphenidate hydrochloride major metabolite (α-phenyl-2-piperidine acetic acid) was 105% (49%-168%) in children and 101% (85%-152%) in adults. The time to peak rate in children was 4.7 hours (1.3-8.2 hours) for the extended-release tablets and 1.9 hours (0.3-4.4 hours) for the tablets. An average of 67% of extended-release tablet dose was excreted in children as compared to 86% in adults.

In a clinical study involving adult subjects who received extended-release tablets, plasma concentrations of methylphenidate hydrochloride’s major metabolite appeared to be greater in females than in males. No gender differences were observed for methylphenidate hydrochloride plasma concentration in the same subjects.
FIELD: medicine. SUBSTANCE: the suggested vaccine with LTB adjuvant contains, at least, one corpuscular immunogen and adjuvant quantity of B subunits of thermolabile enterotoxin characteristic for E.coli. Moreover, adjuvant LTB contains no contaminating A subunits or holotoxin. Vaccine is indicated to be introduced onto mucous membranes and could be applied both for induction of systemic immunoglobulin response and that of general immune response. Isolated LTB free of A subunit and holotoxin is of high adjuvant activity at injecting simultaneously with corpuscular immunogen. EFFECT: higher efficiency. 9 cl, 8 dwg, 9 ex
PURPOSE: To compare the effectiveness and efficiency of a glued (sutureless) technique for amniotic membrane transplantation (AMT) with a traditional sutured one in the setting of acute Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
METHODS: This retrospective cohort study evaluated all patients diagnosed with SJS/TEN between 2008 and 2020 within our hospital network who received AMT in the acute phase according to our protocol and had at least one ophthalmic follow-up in the chronic phase. Primary outcomes included best-corrected visual acuity (BCVA) at the most recent visit, presence of a severe ocular complication (SOC) via predefined criteria, time to procedure and duration of procedure. Random effects model analysis was used to evaluate the impact of potential covariates on outcome measures.
RESULTS: A total of 23 patients (45 eyes) were included: 14 patients (27 eyes) in the AMT suture group and 9 patients (18 eyes) in the AMT glue group. There was no difference between the two groups in BCVA at the most recent visit (p=0.5112) or development of a SOC (p=1.000). The glue method was shorter in duration than the suture method (p<0.001). Random effects model additionally indicated that there was no difference in BCVA at most recent follow-up between patients who had received glued versus sutured AMT (p=0.1460).
CONCLUSIONS: Our glued technique for AMT is as effective as our sutured technique in stabilising the ocular surface and mitigating chronic ocular complications in SJS/TEN. The glued technique is also shorter in duration and performed more expediently than the sutured technique.
BACKGROUND: In South Africa, extragenital etiological sexually transmitted infection (STI) screening among men who have sex with men (MSM) is not routinely available. We aimed to determine the prevalence of STI pathogens at rectal and pharyngeal sites, syphilis seroprevalence, and associated risk factors among a selection of high-risk MSM without symptomatic urethritis attending a men's health clinic in Johannesburg, South Africa.
METHODS: A cross-sectional study was conducted in 2022. Enrolled clients self-reported demographic, sexual behavioral risks, and clinical information. Client or clinician-collected rectal and pharyngeal swabs were tested for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis. C. trachomatis-positive rectal samples were reflex tested for lymphogranuloma venereum. Blood specimens were screened for syphilis. Univariate and multivariate regression models were used to determine factors independently associated with the presence of an extragenital STI or syphilis.
RESULTS: Among the 97 participants (median age, 29 years), 24.7% had an extragenital STI and 9.4% had high nontreponemal antibody titers (rapid plasma reagin ≥1:16). Rectal STIs were detected in 26.4% participants: N. gonorrhoeae (14.3%), C. trachomatis (9.9%), and M. genitalium (5.5%). Pharyngeal STIs were less prevalent (4.1%). Overall, the prevalence of any STI was 41%. Sex under the influence of drugs (adjusted odds ratio, 4.94; 95% confidence interval, 1.56-15.69) and engaging in condomless receptive anal intercourse with a casual partner (adjusted odds ratio, 8.36; 95% confidence interval, 1.73-40.28) were independent risk factors for having an extragenital STI.
CONCLUSIONS: The high burden of extragenital STIs and active syphilis in asymptomatic MSM underscores the importance of routine etiological screening in this key population, as the syndromic approach would not enable detection or treatment of these infections.
The invention discloses a compound radix bupleuri combination medicine used for cold and a preparation method. The combination medicine includes microencapsulated radix bupleuri with a weight percentage being 35%-65% and microencapsulated catechin-tea flavonoids crystals. Because the medicine is processed to be in nanoscale, active ingredients in the medicine are easy to absorb and medicinal effects of the medicine are increased. The beneficial effects of the invention are that the radix bupleuri is processed into a traditional Chinese medicine powder in nanoscale fineness and is manufactured into a compound with saikosaponin, radix bupleuri flavone, ginger and the like, so that nutrition components in the medicine can be absorbed and utilized efficiently. The radix bupleuri is subjected to an emulsification shearing process through microencapsulated liposome so that the radix bupleuri is effectively prevented from oxidative deterioration due to air. The microencapsulated catechin-tea flavone crystal can effectively kill microbes such as aspergillus flavus and dermatophagoides farinae and the like in an infected radix bupleuri during a storage process. Silver ions, which are safe and nontoxic, can absorb microbes and viruses in human organs and cells.
Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.